BioMed Nexus Daily Updates

Your essential biotech, medtech, and pharma recap — no noise, just what matters.

📌TL;DR

Chiesi Group announced a definitive agreement to acquire KalVista Therapeutics (KALV) for $1.9B ($27/share, 40% premium). KalVista's lead product Ekterly is an approved oral treatment for acute attacks in hereditary angioedema (HAE). The deal deepens Chiesi's rare disease portfolio.
AstraZeneca (AZN) beat Q1 2026 estimates with sales topping $15B and expressed increasing confidence in its $80B revenue target by 2030. Key Phase 3 wins in the quarter reinforced the pipeline thesis.
GSK (GSK) reported a Q1 sales beat driven by Shingrix jumping 20% to nearly $1.4B, even as U.S. vaccine skepticism weighed on most of the company's other vaccine franchises. CEO Luke Miels told Fierce Biotech that oncology may offer "the most tempting targets" under GSK's new strategy of outperforming established blockbusters.
AbbVie (ABBV) entered the KRAS oncology space with an option to acquire Kestrel Therapeutics for up to $1.45B, as Kestrel doses patients in a Phase 1 trial of its oral pan-KRAS inhibitor KST-6051.
Eli Lilly (LLY) reports Q1 2026 earnings this morning before the bell. Consensus: $5.88 EPS, $15.23B revenue (36.8% YoY growth). We will cover the results in detail tomorrow.

⚡ Executive Takeaway

Earnings season is separating the winners from the wounded. AstraZeneca beat across the board, passed $15B in quarterly sales, and reaffirmed its $80B 2030 revenue target. GSK found a bright spot in Shingrix while the rest of its vaccine portfolio felt the weight of anti-vaccine sentiment in the U.S. Novartis missed on Tuesday as Entresto fell 42%. Today, all eyes are on Lilly. The consensus expects $15.23B in revenue (up 36.8%) and $5.88 EPS, with analyst estimates revised upward over the past 30 days. Foundayo launch data will be the headline number. Beyond earnings, the M&A wave continues. Chiesi's $1.9B acquisition of KalVista adds another rare disease deal to a 2026 that has seen extraordinary deal volume. AbbVie's option deal with Kestrel Therapeutics puts it in the KRAS oncology race alongside Revolution Medicines, establishing competition for what could be one of the largest oncology markets of the decade. Revolution sued Erasca for patent infringement earlier this week, signaling how aggressively the company is defending its position. The KRAS space is heating up fast. 👉 Read Full Analysis

🔮 What To Watch

Lilly Q1 Results (This Morning): Foundayo TRx trajectory. Zepbound/Mounjaro revenue. ACHIEVE-4 diabetes filing timeline. M&A integration commentary. Tariff positioning. Full coverage in tomorrow's email.
AbbVie/Kestrel KRAS Development: KST-6051 is a pan-KRAS inhibitor, meaning it targets multiple KRAS mutations rather than a single variant. Phase 1 is dosing patients. If data are positive, AbbVie could exercise its option and enter a direct competition with Revolution Medicines' daraxonrasib.
Chiesi/KalVista Integration: Ekterly is approved and generating revenue. Chiesi gets an immediate commercial asset in HAE, a market where Takeda's Takhzyro and BioCryst's Orladeyo are established players.
ASCO (May 31): Revolution Medicines plenary session. Four weeks out.

🏢 Corporate & Business Developments

Chiesi Acquires KalVista for $1.9B to Expand Rare Disease Portfolio KALV
- What Happened: Italy's Chiesi Group announced a definitive agreement on April 29 to acquire KalVista Therapeutics for $27/share in cash, a total equity value of approximately $1.9B and a 40% premium to KalVista's Tuesday closing price. KalVista's lead product, Ekterly, is an FDA-approved oral treatment for acute swelling attacks in patients with hereditary angioedema (HAE), a rare genetic disorder causing severe, unpredictable episodes of swelling.
- Executive Impact: The deal expands Chiesi's rare disease portfolio and gives the Italian company a commercial-stage asset in the HAE market. HAE affects approximately 6,000 to 10,000 people in the U.S. Ekterly competes with Takeda's Takhzyro (injectable, prophylaxis) and BioCryst's Orladeyo (oral, prophylaxis) but is differentiated as an oral acute treatment. The 40% premium reflects the competitive market for rare disease assets with approved products and defined revenue streams. This follows the same playbook seen across 2026 M&A: acquirers paying premium prices for commercial-stage or late-stage rare disease assets with predictable revenue.
AbbVie Enters the KRAS Race with Kestrel Option Deal ABBV
- AbbVie signed an option-to-acquire agreement with Kestrel Therapeutics for up to $1.45B, according to BioSpace. Kestrel is dosing patients in a Phase 1 trial of KST-6051, an oral pan-KRAS inhibitor for solid tumors. Unlike Revolution Medicines' daraxonrasib (which targets the active RAS conformation across multiple variants) or zoldonrasib (G12D-selective), KST-6051 represents a distinct chemical approach to pan-KRAS inhibition. The option structure gives AbbVie the right to acquire Kestrel at a later date, likely contingent on clinical data. This is AbbVie's first entry into the KRAS oncology space.

📊 Earnings

AstraZeneca Beats Q1, Bullish on $80B 2030 Target AZN
- AstraZeneca reported Q1 sales above $15B, beating analyst expectations. Key Phase 3 data wins in the quarter reinforced confidence in the pipeline. Management expressed increasing conviction that the company's $80B revenue target by 2030 is achievable, driven by oncology franchise growth (Enhertu, Tagrisso, Imfinzi), rare disease launches, and respiratory/immunology expansion. AstraZeneca is one of the few large pharma companies projecting accelerating growth through the end of the decade, a contrast to the patent cliff challenges facing Novartis, Merck, and BMS.
GSK Beats on Shingrix, Vaccine Skepticism Weighs on the Rest GSK
- GSK reported a Q1 sales beat driven by Shingrix (shingles vaccine) jumping 20% to nearly $1.4B. However, sales for most of GSK's other vaccines slumped as vaccine skepticism continues to climb in the U.S., a dynamic that has intensified under the current administration's public health messaging. CEO Luke Miels told Fierce Biotech that oncology may offer "the most tempting targets" under GSK's new strategy of trying to outperform established blockbusters rather than build from scratch.

🔬 Clinical & Research Updates

Boehringer Ingelheim and Zealand Pharma Hit Obesity Phase 3
- Boehringer Ingelheim and Zealand Pharma's dual-acting obesity shot met its primary endpoint in a Phase 3 trial, according to BioPharma Dive. The drug was described as "more akin" to Novo Nordisk's Wegovy in terms of weight-loss magnitude, positioning it as a potential competitor in the injectable GLP-1 space. Full results are expected at a medical congress later this year. The obesity market continues to attract new entrants alongside Lilly's Foundayo, Novo's Wegovy/Ozempic, and Kailera's ribupatide.

📅 The Week Ahead

Today: Lilly Q1 earnings (pre-market)
This week/next: Novo Nordisk Q1 earnings (first oral Wegovy revenue)
May 2-5: DDW Annual Meeting
May 6: Royalty Pharma Q1 earnings
May 11: Daiichi Sankyo delayed earnings (tariff impact)
May 12-14: Fierce Biotech Week (Boston)
May 29: FDA RTCT public comment period closes
May 29 to June 2: ASCO Annual Meeting (Chicago)
May 31: ASCO plenary: RASolute 302 full data (RVMD)

👉 Read Full Analysis

🔓 BioMed Nexus Pro: Institutional Intelligence Brief

🧠 The KRAS Competition Heats Up

Three companies are now positioning for the KRAS oncology market:

Revolution Medicines (RVMD): The leader. Daraxonrasib (multi-selective RAS(ON) inhibitor) has Phase 3 data in 2L PDAC (13.2 months OS, HR 0.40), Phase 1/2 data in 1L PDAC (58% ORR combo, 47% mono), and ASCO plenary on May 31. Zoldonrasib (G12D-selective) has AACR plenary data. CNPV NDA filing expected H2 2026. Market cap $30B+. Revolution is suing Erasca for patent infringement.

Erasca: Developing its own RAS inhibitor for pancreatic cancer. AACR data were met with skepticism (BioPharma Dive: "slides despite 'home run' results"). Revolution's patent lawsuit signals concern about competitive positioning.

AbbVie/Kestrel: KST-6051 is a pan-KRAS inhibitor in Phase 1. The option structure means AbbVie is watching the data before committing to a full acquisition. If KST-6051 shows differentiated activity, the $1.45B option price could be a bargain. If not, AbbVie walks away with limited downside.

The KRAS market opportunity is enormous. RAS mutations drive more than 90% of pancreatic cancers, approximately 30% of lung cancers, and significant portions of colorectal and other solid tumors. Revolution's daraxonrasib alone has analyst peak sales estimates of $2B to $4B. A multi-agent KRAS market could exceed $10B at maturity.

💊 Earnings Scorecard: Patent Cliff vs. Pipeline Growth

Company	Q1 Result	Key Metric	Signal
Novartis	Miss	Entresto down 42%	Patent cliff in real time
AstraZeneca	Beat	Sales >$15B, $80B 2030 target	Pipeline-driven growth
GSK	Beat	Shingrix +20% to ~$1.4B	Vaccine skepticism risk
J&J	Beat	Drug sales >$15B	Myeloma franchise driving
Lilly	Today	Consensus $15.23B, +36.8% YoY	Foundayo launch data

The contrast between Novartis (navigating a $4B cliff) and AstraZeneca (accelerating toward $80B) illustrates the divergence in large pharma. Companies that invested in pipeline diversification five years ago are reaping the benefits. Those that did not are scrambling through M&A.

📊 Lilly: What Drops This Morning

Lilly reports Q1 2026 before the bell. Consensus: $5.88 EPS, $15.23B revenue (36.8% YoY growth). StockStory notes that Lilly beat last quarter with $19.29B (42.6% YoY) and guided above Street expectations for the full year.

The five numbers:

Foundayo TRx: How many prescriptions through mid-April? We have Week 1 (1,390, ~2 days). The acceleration curve matters more than the absolute number.
Zepbound/Mounjaro combined revenue: Still the growth engine. Supply chain and demand commentary.
ACHIEVE-4 filing status: Is the T2D CNPV submission on track for end of Q2?
M&A commentary: Six deals in three months (~$21B per BioSpace). Integration strategy.
Full-year guidance: Any revision to 2026 guidance incorporating Foundayo, ACHIEVE-4, and deal costs?

Full coverage of results in tomorrow's email.

🎯 Catalyst Calendar: May 2026 Forward

Date	Event	Tickers
Today	Lilly Q1 earnings	LLY
This week/next	Novo Nordisk Q1 earnings (first oral Wegovy revenue)	NVO
May 2-5	DDW Annual Meeting	Multiple
May 6	Royalty Pharma Q1 earnings	RPRX
May 11	Daiichi Sankyo delayed earnings (tariff impact)	DSNKY
May 12-14	Fierce Biotech Week (Boston)	Multiple
May 29	FDA RTCT public comment period closes	N/A
May 29 to June 2	ASCO Annual Meeting (Chicago)	Multiple
May 31	ASCO plenary: RASolute 302 full data	RVMD
End of Q2	Lilly Foundayo T2D filing under CNPV expected	LLY
Summer 2026	FDA RTCT pilot program launches	Multiple
Late May 2026	Commerce Section 232 report on medical devices expected	MDT, BSX, SYK, ISRG
June 2026	Takeda CEO transition (Julie Kim)	TAK
July 1	Medicare GLP-1 Bridge program launches	LLY, NVO
July 31	Section 232 pharma tariffs effective (large companies)	Multiple
H2 2026	Lilly/Kelonia close expected	LLY
H2 2026	Ajax proof-of-concept data expected	LLY
H2 2026	Beeline Medicines afimetoran Phase 2 SLE readout	Private
H2 2026	Revolution Medicines CNPV NDA filing expected	RVMD
H2 2026	Novo Nordisk Awiqli U.S. launch (first weekly insulin)	NVO
Mid-2026	Lilly retatrutide Phase 3 obesity readouts (TRIUMPH program)	LLY
Sept 19	Ultragenyx UX111 PDUFA (Sanfilippo Type A gene therapy)	RARE
Sept 29	Section 232 pharma tariffs effective (all other companies)	Multiple
Nov 2026	Novartis Entresto European patent expiry begins	NVS
2027	Sun Pharma/Organon close expected	OGN
End of 2026	PhRMA CEO transition	N/A